Evogene Ltd. — Regulatory Filings 2026

Feb 11, 2026

_________ false

����� ��"�	2 381
EVOGENE LTD
Corporation no: 512838723	14299
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C003 ( Public )		Reported via MAGNA:	11/02/2026
	www.isa.gov.il			www.tase.co.il				Reference:	2026-02-014234	Time of broadcast: 12:06 12:06

---

The corporation scheduled the publication of the report to 11/02/2026 15:00Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on	Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

EVGN-Systasy-LMU_PR_final_version_clean_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: -1	Date of revision of form structure: 06/08/2024
Address: Gad Feinstein St 13, P.O.B 2100 , Rehovot 76121   , Tel: 08-9311900 , Fax: 08-9466724
E-mail address: ofer.haviv@evogene.com   Company site: www.evogene.com
Previous names of reporting entity:
Name of the Signatory: Deutsch Nitsan Position of Signatory in the reporting corporation: Chief Legal Officer & Secretary Name of Employer Company:
Address: Gad Feinstein 13 , Rehovot 7638517 Telephone: 08-9311900 Facsimile: 08-9466724 E-mail: nitsan.deutsch@evogene.com 1